Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class ASSE: 688505

Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Application Acceptance Notice for FZ-P001 Sodium Injection for Intraoperative Visualization of Malignant Lesions in Known or Suspected Lung Cancer Patients

· Issued by Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Application Acceptance Notice for FZ-P001 Sodium Injection for Intraoperative Visualization of Malignant Lesions in Known or Suspected Lung Cancer Patients

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis